Ajufo H et al. Impact of symptom benefit and transfusion response on survival in myelofibrosis patients treated with pacritinib: PERSIST-2 landmark survival analysis. ASH 2023;Abstract 3207.
Chifotides HT et al. SOHO state of the art updates and next questions: Novel therapies in development for myelofibrosis. Clin Lymph Myeloma Leuk 2022;22(4):210-23. Abstract
Gill H et al. Phase 2 study to assess the safety and efficacy of bomedemstat (MK3543) in combination with ruxolitinib in patients with myelofibrosis. ASH 2023;Abstract 621.
Goethert JR et al. Bomedemstat (IMG-7289), an LSD1 inhibitor, manages the signs and symptoms of essential thrombocythemia (ET) while reducing the burden of cells homozygous for driver mutations. ASH 2023;Abstract 747.
Gupta V et al. Effect of new or worsening anemia on clinical outcomes in 2233 patients with myelofibrosis treated with ruxolitinib in the expanded-access Jump study. ASH 2023;Abstract 5174.
Harrison CN et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: Results from the phase 3 randomized FREEDOM2 study. ASH 2023;Abstract 3204.
Harrison CN et al. Ruxolitinib treatment in polycythemia vera results in reduction in JAK2 allele burden in addition to improvement in hematocrit control and symptom burden. ASH 2023;Abstract 4553.
Harrison CN et al. Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: Phase II safety and efficacy. J Clin Oncol 2022;40(15):2420-32. Abstract
Koschmieder S et al. Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: Pre-specified interim analysis of the randomized phase 2b Ruxobeat clinical trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN). ASH 2023;Abstract 619.
Letai A. Apoptosis: Directly targeted at last. J Clin Oncol 2022;40(15):1693-5. Abstract
Mesa RA et al. Longitudinal assessment of transfusion intensity in patients with JAK inhibitor-naive or -experienced myelofibrosis treated with momelotinib in the phase 3 Simplify-1 and Momentum trials. ASH 2023;Abstract 3182.
Mohan S et al. Phase 1/2 study of the activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis. ASH2023;Abstract 624.
Pemmaraju N et al. Transform-1: A randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis. ASH 2023;Abstract 620.
Rampal RK et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study. ASH 2023;Abstract 628.
Ritchie EK et al. Durability of hematocrit control in polycythemia vera with a first-in-class hepcidin mimetic rusfertide: Two-year follow up results from the Revive study. ASH 2022;Abstract 745.
Tantravahi SK et al. Selinexor plus ruxolitinib in JAK inhibitor (JAKi)-naïve patients with myelofibrosis: Long-term follow-up from XPORT-MF-034 suggestive of disease modification. ASH 2023;Abstract 622.
Vachhani P et al. Platelet response in pacritinib-treated patients with cytopenic myelofibrosis: A retrospective analysis of PERSIST-2 and PAC203 studies. ASH 2023;Abstract 4554.
Watts JM et al. Bromodomain and extra-terminal inhibitor INCB057643 (LIMBER-103) in patients with relapsed or refractory myelofibrosis and other advanced myeloid neoplasms: A phase 1 study. ASH 2023;Abstract 750.